Feng Jie, Weitner Megan, Shi Wanliang, Zhang Shuo, Zhang Ying
Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore MD, USA.
Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062. eCollection 2016.
Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne disease in the United States and Europe. While the majority of Lyme disease patients can resolve their symptoms if treated promptly, 10-20% of patients suffer from prolonged symptoms called post-treatment Lyme disease syndrome (PTLDS). Although the cause for PTLDS is unclear, one possibility is the presence of bacterial persisters not effectively cleared by the current Lyme antibiotics. Recent studies identified several drug candidates including daptomycin, daunomycin, doxorubicin, and mitomycin C that had good activity against B. burgdorferi persisters. However, their relative activities against B. burgdorferi persisters have not been evaluated under the same conditions. In this study, we tested the anti-persister activities of these drugs against both 7-day and 15-day old stationary phase cultures of B. burgdorferi individually as well as in combination with Lyme antibiotics doxycycline and cefuroxime (Ceftin). Our findings demonstrate daunomycin and daptomycin were more active than mitomycin C in single drug comparison at 10 and 20 μM, as well as in drug combinations with doxycycline and cefuroxime. In addition, daunomycin was more active than doxorubicin which correlated with their ability to stain and accumulate in B. burgdorferi. The two drug combination of doxycycline and cefuroxime was unable to eradicate biofilm-like microcolonies of B. burgdorferi persisters. However, the addition of either daunomycin or daptomycin to the doxycycline + cefuroxime combination completely eradicated the biofilm-like structures and produced no visible bacterial regrowth after 7 and 21 days, while the addition of doxorubicin was unable to prevent regrowth at either 7 or 21 day subculture. Mitomycin C in combination with doxycycline and cefuroxime caused no regrowth at 7 days but visible spirochetal regrowth occurred after 21 day subculture. Furthermore, we found that cefuroxime (Ceftin), the third commonly used and most active antibiotic to treat Lyme disease, could replace cefoperazone (a drug no longer available in the US) in the daptomycin + doxycycline combination with complete eradication of the biofilm-like structures as shown by lack of any regrowth in subcultures. Our findings may have implications for improved treatment of Lyme disease.
莱姆病由伯氏疏螺旋体引起,是美国和欧洲最常见的媒介传播疾病。虽然大多数莱姆病患者如果及时治疗可以缓解症状,但10% - 20%的患者会出现称为治疗后莱姆病综合征(PTLDS)的长期症状。尽管PTLDS的病因尚不清楚,但一种可能性是存在未被目前的莱姆病抗生素有效清除的细菌持留菌。最近的研究确定了几种候选药物,包括达托霉素、柔红霉素、阿霉素和丝裂霉素C,它们对伯氏疏螺旋体持留菌具有良好的活性。然而,它们对伯氏疏螺旋体持留菌相对活性尚未在相同条件下进行评估。在本研究中,我们分别测试了这些药物对7天和15天龄的伯氏疏螺旋体稳定期培养物的抗持留菌活性,以及它们与莱姆病抗生素强力霉素和头孢呋辛(头孢呋辛酯)联合使用时的活性。我们的研究结果表明,在10和20μM的单药比较中,以及在与强力霉素和头孢呋辛联合用药时,柔红霉素和达托霉素比丝裂霉素C更具活性。此外,柔红霉素比阿霉素更具活性,这与其在伯氏疏螺旋体中染色和积累的能力相关。强力霉素和头孢呋辛的两药联合无法根除伯氏疏螺旋体持留菌的生物膜样微菌落。然而,在强力霉素 + 头孢呋辛组合中加入柔红霉素或达托霉素可完全根除生物膜样结构,并且在7天和21天后没有可见的细菌再生长,而加入阿霉素在7天或21天传代培养时均无法防止再生长。丝裂霉素C与强力霉素和头孢呋辛联合使用在7天时没有再生长,但在21天传代培养后出现了可见的螺旋体再生长。此外,我们发现头孢呋辛(头孢呋辛酯)是治疗莱姆病的第三种常用且活性最高的抗生素,在达托霉素 + 强力霉素组合中可以替代头孢哌酮(一种在美国已不再可用的药物),如传代培养中没有任何再生长所示,可完全根除生物膜样结构。我们的研究结果可能对改善莱姆病的治疗具有启示意义。